Hepatitis E: An Emerging Infectious Disease in Germany?

Zusammenfassung

Gestiegene Häufigkeiten von HEV-Infektionen wurden aus verschiedenen Industrienationen berichtet. Wir behaupten, dass dies durch eine gesteigerte Aufmerksamkeit bez. der Erkrankung und nicht durch eine gewachsene Inzidenz erklärt werden kann. Obwohl sich die Anzahl an berichteten HEV-Infektionen in den letzten Jahren mehr als versechsfacht hat, blieb die Seroprävalenz stabil (2 %).

Abstract

Increased frequencies of HEV infections have been reported in several industrialized countries. We suggest that this finding might be explained by a better awareness of the disease and not by an increased incidence. Although reported HEV infections increased more than 6-fold in Germany in recent years, the seroprevalence remained unchanged (2 %).

Schlüsselwörter

Hepatitis E - Infektion - Seroprävalenz - Epidemiologie - Publikationen - HEV

Key words

hepatitis E - infection - seroprevalence - epidemiology - publications - HEV

References

• 1 Pischke S, Wedemeyer H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem?.  Minerva Gastroenterol Dietol. 2010;  56 121-128
• 2 Dalton H R, Bendall R, Ijaz S et al. Hepatitis E: an emerging infection in developed countries.  Lancet Infect Dis. 2008;  8 698-709
• 3 Ijaz S, Vyse A J, Morgan D et al. Indigenous hepatitis E virus infection in England: more common than it seems.  J Clin Virol. 2009;  44 272-276
• 4 Knodler B, Hiller J, Loliger C C et al. Hepatitis e antibodies in blood donors, hemodialysis patients and in normal people.  Beitr Infusionsther Transfusionsmed. 1994;  32 124-127
• 5 Pischke S, Suneetha P V, Baechlein C et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients.  Liver Transpl. 2010;  16 74-82
• 6 Myint K S, Endy T P, Gibbons R V et al. Evaluation of diagnostic assays for hepatitis E virus in outbreak settings.  J Clin Microbiol. 2006;  44 1581-1583
• 7 Dawson G J, Chau K H, Cabal C M et al. Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides.  J Virol Methods. 1992;  38 175-186
• 8 Christensen P B ER, Hjort C, Homburg K M et al. Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark.  Clin Infect Dis. 2008;  47 1026-1031
• 9 Tanaka E, Matsumoto A, Takeda N et al. Age-specific antibody to hepatitis E virus has remained constant during the past 20 years in Japan.  J Viral Hepat. 2005;  12 439-442
• 10 Zhu F C, Zhang J, Zhang X F et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.  Lancet. 2010;  376 (9744) 895-902
• 11 Stoszek S K, Engle R E, Abdel-Hamid M et al. Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities.  Trans R Soc Trop Med Hyg. 2006;  100 89-94
• 12 Wichmann O, Schimanski S, Koch J et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany.  J Infect Dis. 2008;  15 1732-1741